Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label attachment file name title
tabling member	label

Search

1146912

	registered interest
	date	30/09/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what assurance, if any, they have received that medication brought from new sources other than the EU will meet the same standards as present.
	tabling member printed	Baroness Afshar
	uin	HL17886
	answer	answer is ministerial correction date of answer 08/10/2019 answer text <p>All human medicines marketed in the United Kingdom must meet stringent requirements for quality, safety and efficacy set out in UK medicines legislation and supporting guidelines. These apply regardless of the source of the medicine.</p><p>The Medicines and Healthcare products Regulatory Agency (MHRA), the Government body responsible for the safety and licensing of medicines in the UK, regularly inspect pharmaceutical manufacturing plants in the UK and in third countries.</p><p>Regardless of the location of the site of manufacture, the manufacturer must demonstrate to the MHRA that the product is manufactured according to the registered UK licence (marketing authorisation) and to at least the minimum standard detailed in the European Union Guide to Good Manufacturing Practice.</p><p>In addition, each batch of medicine manufactured in a third country is tested within the UK on import and the manufacturing document reviewed by the license holders Qualified Person before being certified for release to the market.</p><p>All these measures will remain in place if the UK leaves the EU.</p> answering member printed Baroness Blackwood of North Oxford question first answered 08/10/2019 14:37:53 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	3847 label Biography information for Baroness Afshar

1674982

	registered interest
	date	04/12/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Osteoporosis: Diagnosis and Medical Treatments
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask His Majesty's Government what estimate they have made of the potential cost savings to (1) the NHS, and (2) employers, in the next 20 years as a result of early detection and treatment of osteoporosis.
	tabling member printed	Baroness Altmann
	uin	HL791
	answer	answer is ministerial correction date of answer 18/12/2023 answer text <p>We have made no estimate of the potential cost savings to the National Health Service, and to employers, in the next 20 years as a result of early detection and treatment of osteoporosis.</p><p>Information on the number of working days lost each year that result from bone fractures is not available. The Office for National Statistics (ONS) Sickness absence in the United Kingdom labour market publication is produced from data collected from the Labour Force Survey; however, this survey does not specifically ask the question of sick days taken due to fractures.</p><p>A document is attached with tables showing, firstly, the number of deaths where bone fractures were the secondary cause of death, by broad age group and sex, registered between 2014 and 2023 in England and Wales; and secondly, the number of deaths involving bone fractures, by broad age group and sex, registered between 2014 and 2023 in England and Wales.</p><p>Government will continue to consider options for further work to support those with osteoporosis and at risk of fractures, including working together with NHS England to explore supporting the provision of fracture liaison service.</p> answering member printed Lord Markham grouped question UIN HL792 question first answered 18/12/2023 17:39:04 answering member 4948 label Biography information for Lord Markham attachment 1 file name FORMATTED TABLES FOR MINISTERIAL CLEARANCE HL792 (3).xlsx title Attachment
	tabling member	4533 label Biography information for Baroness Altmann

1674983

	registered interest
	date	04/12/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Fractures: Death and Sick Leave
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask His Majesty's Government what estimates they have made of the number of (1) deaths and (2) working days lost, each year that result from bone fractures among (a) women, and (b) men.
	tabling member printed	Baroness Altmann
	uin	HL792
	answer	answer is ministerial correction date of answer 18/12/2023 answer text <p>We have made no estimate of the potential cost savings to the National Health Service, and to employers, in the next 20 years as a result of early detection and treatment of osteoporosis.</p><p>Information on the number of working days lost each year that result from bone fractures is not available. The Office for National Statistics (ONS) Sickness absence in the United Kingdom labour market publication is produced from data collected from the Labour Force Survey; however, this survey does not specifically ask the question of sick days taken due to fractures.</p><p>A document is attached with tables showing, firstly, the number of deaths where bone fractures were the secondary cause of death, by broad age group and sex, registered between 2014 and 2023 in England and Wales; and secondly, the number of deaths involving bone fractures, by broad age group and sex, registered between 2014 and 2023 in England and Wales.</p><p>Government will continue to consider options for further work to support those with osteoporosis and at risk of fractures, including working together with NHS England to explore supporting the provision of fracture liaison service.</p> answering member printed Lord Markham grouped question UIN HL791 question first answered 18/12/2023 17:39:04 answering member 4948 label Biography information for Lord Markham attachment 1 file name FORMATTED TABLES FOR MINISTERIAL CLEARANCE HL792 (3).xlsx title Attachment
	tabling member	4533 label Biography information for Baroness Altmann

1230945

	registered interest
	date	02/09/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer: Health Services
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government how many people they estimate have missed cancer treatment since March in (1) England and Wales, (2) Scotland, and (3) Northern Ireland; and what estimate they have made of the impact of this on future cancer mortality statistics.
	tabling member printed	Baroness Altmann
	uin	HL7578
	answer	answer is ministerial correction date of answer 08/10/2020 answer text <p>In England, there have been no estimates made of this kind. The Government cannot comment for Wales, Scotland or Northern Ireland as this is a devolved matter.</p><p>The long-term consequences of the COVID-19 pandemic on service provision and outcomes will be widespread and complex to identify and evaluate.</p><p>Critical care services, including for heart disease and stroke, as well as urgent and essential cancer treatments have remained open and continued throughout the pandemic, and have not been interrupted. The data show that the timeliness and quality of care have been broadly equivalent to, or better than, pre-COVID-19.</p> answering member printed Lord Bethell grouped question UIN HL7579 question first answered 08/10/2020 11:26:25 answering member 4708 label Biography information for Lord Bethell
	tabling member	4533 label Biography information for Baroness Altmann

1230946

	registered interest
	date	02/09/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Health Services: Death
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what estimate they have made of the number of people likely to die during 2020 as a result of interruption to normal medical services, in particular (1) the failure to carry out cancer assessments or treatment, (2) individuals suffering stroke but not receiving timely treatment, and (3) individuals not receiving treatment for heart disease in normal timescales.
	tabling member printed	Baroness Altmann
	uin	HL7579
	answer	answer is ministerial correction date of answer 08/10/2020 answer text <p>In England, there have been no estimates made of this kind. The Government cannot comment for Wales, Scotland or Northern Ireland as this is a devolved matter.</p><p>The long-term consequences of the COVID-19 pandemic on service provision and outcomes will be widespread and complex to identify and evaluate.</p><p>Critical care services, including for heart disease and stroke, as well as urgent and essential cancer treatments have remained open and continued throughout the pandemic, and have not been interrupted. The data show that the timeliness and quality of care have been broadly equivalent to, or better than, pre-COVID-19.</p> answering member printed Lord Bethell grouped question UIN HL7578 question first answered 08/10/2020 11:26:25 answering member 4708 label Biography information for Lord Bethell
	tabling member	4533 label Biography information for Baroness Altmann

1588979

	registered interest
	date	23/02/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Coronavirus: Immunosuppression
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask His Majesty's Government, further to the finding from the National Institute for Health and Care Excellence (NICE) that "Evusheld is not recommended for vulnerable adults who are at high risk of severe COVID-19 because there is not enough evidence of its effectiveness against current variants and those likely to be circulating in the next 6 months", what consideration they have given to using human-derived convalescent plasma for immune compromised individuals; and what trials they have undertaken, if any, to test its effectiveness.
	tabling member printed	Baroness Altmann
	uin	HL5825
	answer	answer is ministerial correction date of answer 02/03/2023 answer text <p>For treatment of patients with COVID-19, the REMAP-CAP and RECOVERY trials both found convalescent plasma did not provide any benefit to the overall patient group. However, detailed analysis within subgroups of the REMAP-CAP data found there was a likelihood that people who are immunosuppressed may benefit from convalescent plasma with very high antibody levels - unfortunately there was insufficient data for a definite result. Consequently, REMAP-CAP has now decided to reopen the convalescent plasma arm to collect more data.</p><p> </p><p>Further research is needed to determine the benefit of using human-derived convalescent plasma, or products derived from it, for immunocompromised individuals before this could be approved and available to patients. The Department commissions research through the National Institute for Health and Care Research (NIHR). NIHR welcomes funding applications for research into any aspect of human health, including immunoglobulins and convalescent plasma.</p> answering member printed Lord Markham grouped question UIN HL5826 question first answered 02/03/2023 13:13:10 answering member 4948 label Biography information for Lord Markham
	tabling member	4533 label Biography information for Baroness Altmann

1588980

	registered interest
	date	23/02/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Coronavirus: Immunosuppression
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask His Majesty's Government, further to (1) the Written Answer by Lord Markham on 20 February (HL5171), and (2) the conclusion from the National Institute for Health and Care Excellence (NICE) that "Evusheld is not recommended for vulnerable adults who are at high risk of severe COVID-19 because there is not enough evidence of its effectiveness against current variants and those likely to be circulating in the next 6 months", what steps they will now take to ensure that immunocompromised individuals have access to passive immunisation via relevant human-derived antibody products from convalescent plasma, instead of through monoclonal antibody treatments.
	tabling member printed	Baroness Altmann
	uin	HL5826
	answer	answer is ministerial correction date of answer 02/03/2023 answer text <p>For treatment of patients with COVID-19, the REMAP-CAP and RECOVERY trials both found convalescent plasma did not provide any benefit to the overall patient group. However, detailed analysis within subgroups of the REMAP-CAP data found there was a likelihood that people who are immunosuppressed may benefit from convalescent plasma with very high antibody levels - unfortunately there was insufficient data for a definite result. Consequently, REMAP-CAP has now decided to reopen the convalescent plasma arm to collect more data.</p><p> </p><p>Further research is needed to determine the benefit of using human-derived convalescent plasma, or products derived from it, for immunocompromised individuals before this could be approved and available to patients. The Department commissions research through the National Institute for Health and Care Research (NIHR). NIHR welcomes funding applications for research into any aspect of human health, including immunoglobulins and convalescent plasma.</p> answering member printed Lord Markham grouped question UIN HL5825 question first answered 02/03/2023 13:13:10 answering member 4948 label Biography information for Lord Markham
	tabling member	4533 label Biography information for Baroness Altmann

1191468

	registered interest
	date	28/04/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Care Homes: Finance
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what assessment they have made of the financial strength of the companies in charge of the majority of elderly care homes.
	tabling member printed	Baroness Altmann
	uin	HL3648
	answer	answer is ministerial correction date of answer 12/05/2020 answer text <p>The Care Quality Commission (CQC) monitors the financial health of the largest and most difficult-to-replace adult social care providers through their Market Oversight Scheme. Under the scheme, they have a duty to notify local authorities if they consider that a provider’s services are likely to be disrupted because of business failure. This allows local authorities time to step in and ensure that people continue to receive the services they need. As a minimum, all providers in the Market Oversight Scheme are required to provide the CQC with financial information on a quarterly basis. However, where the CQC perceives a greater risk to continuity of care, more regular engagement is undertaken.</p><p>We recognise the pressures that all parts of the sector are facing, and we have provided councils with £1.6 billion funding in March to help local authorities deal with the immediate impacts of COVID-19. On top of this, on 18 April the Secretary of State for Housing, Communities and Local Government announced an additional £1.6 billion of funding to support local authorities delivering essential frontline services.</p> answering member printed Lord Bethell grouped question UIN HL3649 question first answered 12/05/2020 15:36:47 answering member 4708 label Biography information for Lord Bethell
	tabling member	4533 label Biography information for Baroness Altmann

1191469

	registered interest
	date	28/04/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Care Homes: Finance
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government whether there are any regulations or requirements placed on owners of care homes to demonstrate financial strength; and what plans they have, if any, to place limits on the level of debt such companies may be allowed to have.
	tabling member printed	Baroness Altmann
	uin	HL3649
	answer	answer is ministerial correction date of answer 12/05/2020 answer text <p>The Care Quality Commission (CQC) monitors the financial health of the largest and most difficult-to-replace adult social care providers through their Market Oversight Scheme. Under the scheme, they have a duty to notify local authorities if they consider that a provider’s services are likely to be disrupted because of business failure. This allows local authorities time to step in and ensure that people continue to receive the services they need. As a minimum, all providers in the Market Oversight Scheme are required to provide the CQC with financial information on a quarterly basis. However, where the CQC perceives a greater risk to continuity of care, more regular engagement is undertaken.</p><p>We recognise the pressures that all parts of the sector are facing, and we have provided councils with £1.6 billion funding in March to help local authorities deal with the immediate impacts of COVID-19. On top of this, on 18 April the Secretary of State for Housing, Communities and Local Government announced an additional £1.6 billion of funding to support local authorities delivering essential frontline services.</p> answering member printed Lord Bethell grouped question UIN HL3648 question first answered 12/05/2020 15:36:47 answering member 4708 label Biography information for Lord Bethell
	tabling member	4533 label Biography information for Baroness Altmann

1135681

	registered interest
	date	01/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Continuing Care: Finance
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what estimate they have made of the number of applications received for NHS Continuing Healthcare Funding in England in each of the last three years.
	tabling member printed	Baroness Altmann
	uin	HL16774
	answer	answer is ministerial correction date of answer 15/07/2019 answer text <p>The following table provides the total number of referrals received for NHS Continuing Healthcare (CHC) for both Standard and Fast Track NHS CHC, for the years 2016/17 to 2018/19.</p><table><tbody><tr><td colspan="3"><p>Number of Referrals Received</p></td></tr><tr><td><p>Period</p></td><td><p>Standard NHS CHC</p></td><td><p>Fast Track</p></td><td><p>Total NHS CHC</p></td></tr><tr><td><p>2016/17</p></td><td><p>76,945</p></td><td><p>88,420</p></td><td><p>165,365</p></td></tr><tr><td><p>2017/18</p></td><td><p>75,322</p></td><td><p>94,175</p></td><td><p>169,497</p></td></tr><tr><td><p>2018/19</p></td><td><p>73,475</p></td><td><p>97,273</p></td><td><p>170,748</p></td></tr></tbody></table><p> </p><p>NHS England collects and publishes data regarding the number of referrals completed, and of those, how many were assessed as eligible (as a percentage). A table showing these figures is attached due to the size of the data. The percentage of referrals agreed as eligible is based on the number of referrals ‘completed’ (rather than ‘referrals received’). Pre 2017/18 data did not use this counting methodology and therefore is not comparable. 2016/17 figures have therefore not been included.</p><p>The NHS CHC appeals process consists of clinical commissioning group local resolution and NHS England Independent Review. It is not possible to provide data on cases found eligible at local review or Independent Review as a percentage of applications initially assessed as not eligible.</p><p>We do not hold information on the percentage of NHS CHC referrals which were assessed as eligible within the requested time periods. NHS England does, however, hold information on the percentage of referrals completed within 28 days, and the latest annual information on this is included in the following table. This relates to Standard NHS CHC and not Fast Track NHS CHC.</p><p> </p><table><tbody><tr><td colspan="3"><p>% referrals within 28 days</p></td></tr><tr><td><p>Period</p></td><td colspan="3"><p>Standard NHS CHC</p></td></tr><tr><td><p> </p></td><td><p>Referrals completed</p></td><td><p>Referrals completed in 28 days</p></td><td><p>% completed in 28 days</p></td></tr><tr><td><p>2018/19</p></td><td><p>76,803</p></td><td><p>53,504</p></td><td><p>70%</p></td></tr></tbody></table><p> </p><p> </p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL16775 HL16776 HL16777 question first answered 15/07/2019 10:21:24 answering member 4019 label Biography information for Baroness Blackwood of North Oxford attachment 1 file name HL16774 data table formatted.docx title NHS CHC Referrals completed
	tabling member	4533 label Biography information for Baroness Altmann